-
1Academic Journal
Συγγραφείς: Анцыборов Андрей Викторович, Andrey V. Antsyborov, Дубатова Ирина Владимировна, Irina V. Dubatova
Πηγή: Interactive science; № 6(40); 57-67 ; Интерактивная наука; № 6(40); 57-67 ; ISSN: 2414-9411 ; 2414-9411 ; ISSN(electronic Version): 2500-2686 ; 2500-2686
Θεματικοί όροι: лабораторная диагностика, drug addiction, наркотическая зависимость, синтетические катиноны, designer drugs, psychosis, synthetic cathinone, new psychoactive substances, laboratory diagnostics, phenethylamines, synthetic cannabimimetic, phencyclidine, новые психоактивные вещества, фенэтиламины, фенциклидины, synthetic tryptamines, «дизайнерские» наркотики, синтетические каннабимиметики, синтетические триптамины, психотические нарушения
Περιγραφή αρχείου: text/html
Relation: info:eu-repo/semantics/altIdentifier/pissn/2414-9411; info:eu-repo/semantics/altIdentifier/eissn/2500-2686; Monthly international scientific journal Interactive science Issue 6(40); https://interactive-plus.ru/e-articles/644/Action644-497066.pdf; European Monitoring Centre for Drugs and Drug Addiction. EMCDDA-Europol 2013 annual report on the implementation of council decision 2005/387/JHA. – 2014.; United Nations Office on Drugs and Crime. Global Synthetic Drugs Assessment: Amphetamine-type Stimulants and New Psychoactive Substances. – United Nations Office on Drugs and Crime, 2014.; Nelson M. E., Bryant S. M., Aks S. E. Emerging drugs of abuse //Emergency Medicine Clinics. – 2014. – Т. 32. – №. 1. – С. 1–28.; Deluca P. et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project //Progress in Neuro-Psychopharmacology and Biological Psychiatry. – 2012. – Т. 39. – №. 2. – С. 221–226.; Van Hout M. C., Bingham T. «Silk Road’, the virtual drug marketplace: A single case study of user experiences //International Journal of Drug Policy. – 2013. – Т. 24. – №. 5. – С. 385–391.; Papanti D. et al. «Spiceophrenia»: a systematic overview of «Spice»-related psychopathological issues and a case report //Human Psychopharmacology: Clinical and Experimental. – 2013. – Т. 28. – №. 4. – С. 379–389.; Schifano F. Drug abuse: treatment and management //Substance Abuse Disorders. – 2009. – С. 53–74.; Schifano F. Novel psychoactive substances (NPS): clinical and pharmacological issues //Drugs and Alcohol Today. – 2015. – Т. 15. – №. 1. – С. 21–27.; Schifano F. Novel psychoactive substances also known as «legal highs’ //Annual report of the Chief Medical Officer. – 2013.; Lonati D. et al. MAM-2201 (analytically confirmed) intoxication after «synthacaine» consumption //Annals of emergency medicine. – 2014. – Т. 64. – №. 6. – С. 629–632.; Aranda E. et al. Use of novel psychoactive substances (NPS): a description of a harm reduction center in Barcelona //Res Adv Psychiatry. – 2014. – Т. 1. – №. Suppl 1. – С. 36.; Vandrey R. et al. A survey study to characterize use of Spice products (synthetic cannabinoids) //Drug and alcohol dependence. – 2012. – Т. 120. – №. 1–3. – С. 238–241.; Kikura-Hanajiri R. et al. Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012 //Forensic Toxicology. – 2013. – Т. 31. – №. 1. – С. 44–53.; Ogata J. et al. DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs //Forensic science international. – 2013. – Т. 227. – №. 1–3. – С. 33–41.; Park Y. et al. Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-methoxybenzoyl) indole //Forensic Toxicology. – 2013. – Т. 31. – №. 2. – С. 187–196.; Uchiyama N. et al. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products //Forensic science international. – 2013. – Т. 227. – №. 1–3. – С. 21–32.; Uchiyama N. et al. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl) (1-pentyl-1H-indol-3-yl) methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3, 4, 5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products //Forensic Toxicology. – 2014. – Т. 32. – №. 1. – С. 105–115.; Uchiyama N. et al. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products //Forensic Toxicology. – 2013. – Т. 31. – №. 2. – С. 223–240.; Dresen S. et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds //Journal of Mass Spectrometry. – 2010. – Т. 45. – №. 10. – С. 1186–1194.; Wurita A. et al. A large amount of new designer drug diphenidine coexisting with a synthetic cannabinoid 5-fluoro-AB-PINACA found in a dubious herbal product //Forensic Toxicology. – 2014. – Т. 32. – №. 2. – С. 331–337.; Choi H. et al. Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS //Analytical and bioanalytical chemistry. – 2013. – Т. 405. – №. 12. – С. 3937–3944.; Fattore L., Fratta W. Beyond THC: the new generation of cannabinoid designer drugs //Frontiers in behavioral neuroscience. – 2011. – Т. 5. – С. 60.; Brents L. K., Prather P. L. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products //Drug metabolism reviews. – 2014. – Т. 46. – №. 1. – С. 72–85.; Pertwee R. G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists //Current medicinal chemistry. – 2010. – Т. 17. – №. 14. – С. 1360–1381.; Papanti D. et al. «Noids» in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics //Advances in Dual Diagnosis. – 2014. – Т. 7. – №. 3. – С. 137–148.; Fišar Z. Inhibition of monoamine oxidase activity by cannabinoids //Naunyn-Schmiedeberg's archives of pharmacology. – 2010. – Т. 381. – №. 6. – С. 563–572.; Morgan D. et al. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications //Neuropharmacology. – 2013. – Т. 72. – С. 274–281.; Halberstadt A. L. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens //Behavioural brain research. – 2015. – Т. 277. – С. 99–120.; Wells D. L., Ott C. A. The «new» marijuana //Annals of Pharmacotherapy. – 2011. – Т. 45. – №. 3. – С. 414–417.; Yip L., Dart R. C. Is there something more about synthetic cannabinoids? //Forensic Toxicology. – 2014. – Т. 32. – №. 2. – С. 340–341.; Wilkinson S. M., Banister S. D., Kassiou M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids //Australian Journal of Chemistry. – 2015. – Т. 68. – №. 1. – С. 4–8.; Hermanns-Clausen M. et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings //Addiction. – 2013. – Т. 108. – №. 3. – С. 534–544.; Spaderna M., Addy P. H., D’Souza D. C. Spicing things up: synthetic cannabinoids //Psychopharmacology. – 2013. – Т. 228. – №. 4. – С. 525–540.; Winstock A. R., Barratt M. J. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products //Human Psychopharmacology: Clinical and Experimental. – 2013. – Т. 28. – №. 4. – С. 390–393.; Freeman M. J. et al. Ischemic stroke after use of the synthetic marijuana «spice» //Neurology. – 2013. – Т. 81. – №. 24. – С. 2090–2093.; Mir A. et al. Myocardial infarction associated with use of the synthetic cannabinoid K2 //Pediatrics. – 2011. – Т. 128. – №. 6. – С. e1622-e1627.; Murphy T. D. et al. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012 //MMWR. Morbidity and mortality weekly report. – 2013. – Т. 62. – №. 6. – С. 93.; Saito T. et al. A fatal case of MAM-2201 poisoning //Forensic Toxicology. – 2013. – Т. 31. – №. 2. – С. 333–337.; Shanks K. G., Dahn T., Terrell A. R. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework //Journal of Analytical Toxicology. – 2012. – Т. 36. – №. 3. – С. 145–152.; Schaefer N. et al. A fatal case involving several synthetic cannabinoids //Toxichem Krimtech. – 2013. – Т. 80. – №. Spec Iss. – С. 248–251.; Savasman C. M. et al. Two fatalities due to the use of synthetic cannabinoids alone //66th Annual Meeting of the American Academy of Forensic Sciences, Seattle. Denver: Publication Printers Inc. – 2014. – Т. 316.; Patton A. L. et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure //Journal of forensic sciences. – 2013. – Т. 58. – №. 6. – С. 1676–1680.; Behonick G. et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22 //Journal of analytical toxicology. – 2014. – Т. 38. – №. 8. – С. 559–562.; Corkery J. et al. Drug-related deaths in the UK: January-December 2012 //Annual report. – 2013.; Elliott S., Evans J. A 3-year review of new psychoactive substances in casework //Forensic science international. – 2014. – Т. 243. – С. 55–60.; Kronstrand R. et al. Toxicological findings of synthetic cannabinoids in recreational users //Journal of analytical toxicology. – 2013. – Т. 37. – №. 8. – С. 534–541.; Rosenbaum C. D. et al. K2 & Spice abusers: a case series of clinical and laboratory findings //CLINICAL TOXICOLOGY. – 52 VANDERBILT AVE, NEW YORK, NY 10017 USA: INFORMA HEALTHCARE, 2011.-Т. 49. – №. 6. – С. 528–528.; Wikström M. et al. An accidental fatal intoxication with methoxetamine //Journal of analytical toxicology. – 2012. – Т. 37. – №. 1. – С. 43–46.; Gunderson E. W. et al. «Spice» and «K2» herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans //The American journal on addictions. – 2012. – Т. 21. – №. 4. – С. 320–326.; Nacca N. et al. The synthetic cannabinoid withdrawal syndrome //Journal of addiction medicine. – 2013. – Т. 7. – №. 4. – С. 296–298.; Rominger A. et al. Effects of acute detoxification of the herbal blend «Spice Gold» on dopamine D2/3 receptor availability: a [18F] fully pride PET study //European Neuropsychopharmacology. – 2013. – Т. 23. – №. 11. – С. 1606–1610.; Zimmermann U. S. et al. Withdrawal phenomena and dependence syndrome after the consumption of «spice gold» //Deutsches Ärzteblatt International. – 2009. – Т. 106. – №. 27. – С. 464.; Celofiga A., Koprivsek J., Klavz J. Use of synthetic cannabinoids in patients with psychotic disorders: case series //Journal of dual diagnosis. – 2014. – Т. 10. – №. 3. – С. 168–173.; Oluwabusi O. O. et al. Synthetic cannabinoid-induced psychosis: two adolescent cases //Journal of child and adolescent psychopharmacology. – 2012. – Т. 22. – №. 5. – С. 393–395.; Papaseit E. et al. Human pharmacology of mephedrone: A dose-finding pilot study //Abstracts/Drug and Alcohol Dependence. – 2015. – Т. 146. – С. e34-e117.; Schifano F., Corkery J., Ghodse A. H. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, «meow meow») in the United Kingdom //Journal of clinical psychopharmacology. – 2012. – Т. 32. – №. 5. – С. 710–714.; Corkery J. M., Schifano F., Ghodse A. H. Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues //Pharmacology. – Intech Open, 2012.; Corkery J. M. et al. «Bundle of fun or «bunch of problems»? Case series of khat-related deaths in the UK //Drugs: education, prevention and policy. – 2011. – Т. 18. – №. 6. – С. 408–425.; Loi B. et al. Deaths of individuals aged 16–24 years in the UK after using mephedrone //Human Psychopharmacology: Clinical and Experimental. – 2015. – Т. 30. – №. 4. – С. 225–232.; Warrick B. J. et al. Lethal serotonin syndrome after methylone and butylone ingestion //Journal of Medical Toxicology. – 2012. – Т. 8. – №. 1. – С. 65–68.; Schifano F. et al. Mephedrone (4-methylmethcathinone; «meow meow»): chemical, pharmacological and clinical issues //Psychopharmacology. – 2011. – Т. 214. – №. 3. – С. 593–602.; Bosak A., LoVecchio F., Levine M. Recurrent seizures and serotonin syndrome following «2C-I» ingestion //Journal of medical toxicology. – 2013. – Т. 9. – №. 2. – С. 196–198.; Topeff J. M. et al. A case series of symptomatic patients, including one fatality, following 2C-E exposure //Clinical Toxicology. – 52 VANDERBILT AVE, NEW YORK, NY 10017 USA: INFORMA HEALTHCARE, 2011. – Т. 49. – №. 6. – С. 526–526.; Schifano F. et al. Comparison between amphetamine/methylamphetamine and ecstasy (MDMA, MDEA, MDA, 4-MTA) mortality data in the UK (1997–2007) //Neuropsychobiology. – 2010. – Т. 61. – №. 3. – С. 122–30.; Winstock A., Schifano F. Disorders relating to the use of ecstasy, other «party drugs» and khat //New Oxford textbook of psychiatry. – 2009. – С. 3.5.; Corazza O. et al. Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly //Current clinical pharmacology. – 2011. – Т. 6. – №. 2. – С. 125–129.; Bersani F. S. et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug //BioMed Research International. – 2014. – Т. 2014.; Lindeman E. et al. MT-45-en livsfarlig och potentiellt ototoxisk internetdrog //Lakartidningen. – 2014. – Т. 111. – С. CZR4.; Shulgin A., Shulgin A. TIHKAL: the continuation. – Berkeley: Transform Press, 1997. – Т. 546.; Sanders B. et al. «Research chemicals»: tryptamine and phenethylamine use among high-risk youth //Substance use and misuse. – 2008. – Т. 43. – №. 3–4. – С. 389–402.; Arunotayanun W. et al. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging «novel psychoactive drugs’ //Bioorganic & medicinal chemistry letters. – 2013. – Т. 23. – №. 11. – С. 3411–3415.; Collins M. Some new psychoactive substances: Precursor chemicals and synthesis-driven end-products //Drug testing and analysis. – 2011. – Т. 3. – №. 7–8. – С. 404–416.; Lessin A. W., Long R. F., Parkes M. W. Central stimulant actions of α-alkyl substituted tryptamines in mice //British journal of pharmacology and chemotherapy. – 1965. – Т. 24. – №. 1. – С. 49–67.; Dargan P., Wood D. (ed.). Novel psychoactive substances: classification, pharmacology and toxicology. – Academic Press, 2013.; Cozzi N. V. et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter //Journal of neural transmission. – 2009. – Т. 116. – №. 12. – С. 1591.; Fantegrossi W. E., Murnane K. S., Reissig C. J. The behavioral pharmacology of hallucinogens //Biochemical pharmacology. – 2008. – Т. 75. – №. 1. – С. 17–33.; Nichols D. E. Hallucinogens //Pharmacology & therapeutics. – 2004. – Т. 101. – №. 2. – С. 131–181.; Fontanilla D. et al. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator //Science. – 2009. – Т. 323. – №. 5916. – С. 934–937.; Sogawa C. et al. 5-Methoxy-N, N-diisopropyltryptamine («Foxy»), a selective and high affinity inhibitor of serotonin transporter //Toxicology letters. – 2007. – Т. 170. – №. 1. – С. 75–82.; Ujváry I. Psychoactive natural products: overview of recent developments //Annali dell'Istituto superiore di sanita. – 2014. – Т. 50. – С. 12–27.; Lyttle T., Goldstein D., Gartz J. Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic //Journal of Psychoactive Drugs. – 1996. – Т. 28. – №. 3. – С. 267–290.; Wilcox J. Psychoactive properties of alpha-methyltryptamine: analysis from self-reports of users //Journal of psychoactive drugs. – 2012. – Т. 44. – №. 3. – С. 274–276.; Morris H., Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs //Drug testing and analysis. – 2014. – Т. 6. – №. 7–8. – С. 614–632.; Kersten B. P., McLaughlin M. E. Toxicology and management of novel psychoactive drugs //Journal of pharmacy practice. – 2015. – Т. 28. – №. 1. – С. 50–65.; Schifano F. et al. Novel psychoactive substances of interest for psychiatry //World Psychiatry. – 2015. – Т. 14. – №. 1. – С. 15–26.; Анцыборов А. В., Асадуллин А. Р. Психоактивные эффекты и токсические реакции, связанные с употреблением мефедрона и метилона (обзор литературы) //Интерактивная наука. – 2017. – №. 19.; Анцыборов А. В., Мрыхин В. В. Синтетические катиноны «Соли для ванн»: механизм действия, токсикологические аспекты, клиника, формирование зависимости //Интерактивная наука. – 2017. – №. 15.; Мрыхин В. В., Анцыборов А. В. Психиатрические аспекты употребления дизайнерских наркотиков и новых психоактивных веществ //Интерактивная наука. – 2017. – №. 12.; Анцыборов А. В., Мрыхин В. В. Синтетические каннабиноиды: распространённость, механизмы формирования зависимости, психические нарушения, связанные с употреблением. Современное состояние проблемы //Интерактивная наука. – 2017. – №. 14.; European Monitoring Centre for Drugs and Drug Addiction. EMCDDA-Europol 2013 annual report on the implementation of council decision 2005.; (2014). United Nations Office on Drugs and Crime. Global Synthetic Drugs Assessment: Amphetamine-type Stimulants and New Psychoactive Substances. Drugs and Crime.; Nelson, M. E., Bryant, S. M., & Aks, S. E. (2014). Emerging drugs of abuse. Emergency Medicine Clinics , T. 32 , 1 , 1-28.; Deluca, P. (2012). et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Progress in Neuro-Psychopharmacology and Biological Psychiatry , T. 39 , 2 , 221-226.; Hout, M. C., & Bingham, T. (2013). Van, "Silk Road', the virtual drug marketplace: A single case study of user experiences. International Journal of Drug Policy , T. 24 , 5 , 385-391.; Papanti, D. (2013). et al. "Spiceophrenia": a systematic overview of "Spice"-related psychopathological issues and a case report. Human Psychopharmacology: Clinical and Experimental , T. 28 , 4 , 379-389.; Schifano, F. (2009). Drug abuse: treatment and management. Substance Abuse Disorders , S. 53 .; Schifano, F. (2015). Novel psychoactive substances (NPS): clinical and pharmacological issues. Drugs and Alcohol Today , T. 15 , 1 , 21-27.; Schifano, F. (2013). Novel psychoactive substances also known as "legal highs'. Annual report of the Chief Medical Officer .; Lonati, D. (2014). et al. MAM-2201 (analytically confirmed) intoxication after "synthacaine" consumption. Annals of emergency medicine , T. 64 , 6 , 629-632.; Aranda, E. (2014). et al. Use of novel psychoactive substances (NPS): a description of a harm reduction center in Barcelona. Res Adv Psychiatry , T. 1 , 1 , 36.; Vandrey, R. (2012). et al. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug and alcohol dependence , T. 120 , 1 , 238-241.; Kikura-Hanajiri, R. (2013). et al. Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicology , T. 31 , 1 , 44-53.; Ogata, J. (2013). et al. DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs. Forensic science international , T. 227 , 1 , 33-41.; Park, Y. (2013). et al. Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-methoxybenzoyl) indole. Forensic Toxicology , T. 31 , 2 , 187-196.; Uchiyama, N. (2013). et al. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic science international , T. 227 , 1 , 21-32.; Uchiyama, N. (2014). et al. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl) (1-pentyl-1H-indol-3-yl) methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3, 4, 5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-. Forensic Toxicology , T. 32 , 1 , 105-115.; Uchiyama, N. (2013). et al. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative a-PVT and an opioid receptor agonis. Forensic Toxicology , T. 31 , 2 , 223-240.; Dresen, S. (2010). et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. Journal of Mass Spectrometry , T. 45 , 10 , 1186-1194.; Wurita, A. (2014). et al. A large amount of new designer drug diphenidine coexisting with a synthetic cannabinoid 5-fluoro-AB-PINACA found in a dubious herbal product. Forensic Toxicology , T. 32 , 2 , 331-337.; Choi, H. (2013). et al. Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Analytical and bioanalytical chemistry , T. 405 , 12 , 3937-3944.; Fattore, L., & Fratta, W. (2011). Beyond THC: the new generation of cannabinoid designer drugs. Frontiers in behavioral neuroscience , T. 5 , 60.; Brents, L. K., & Prather, P. L. (2014). The K2. Drug metabolism reviews , T. 46 , 1 , 72-85.; Pertwee, R. G. (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Current medicinal chemistry , T. 17 , 14 , 1360-1381.; Papanti, D. (2014). et al. "Noids" in a nutshell: everything you (don't) want to know about synthetic cannabimimetics. Advances in Dual Diagnosis , T. 7 , 3 , 137-148.; Fisar, Z. (2010). Inhibition of monoamine oxidase activity by cannabinoids. Naunyn-Schmiedeberg's archives of pharmacology , T. 381 , 6 , 563-572.; Morgan, D. (2013). et al. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications. Neuropharmacology , T. 72 , 274-281.; Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural brain research , T. 277 , 99-120.; Wells, D. L., & Ott, C. A. (2011). The "new" marijuana. Annals of Pharmacotherapy , T. 45 , 3 , 414-417.; Yip, L., & Dart, R. C. (2014). Is there something more about synthetic cannabinoids?. Forensic Toxicology , T. 32 , 2 , 340-341.; Wilkinson, S. M., Banister, S. D., & Kassiou, M. (2015). Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Australian Journal of Chemistry , T. 68 , 1 , 4-8.; Hermanns-Clausen, M. (2013). et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction , T. 108 , 3 , 534-544.; Spaderna, M., & Addy, P. H. (2013). D'Souza D. C. Spicing things up: synthetic cannabinoids. Psychopharmacology , T. 228 , 4 , 525-540.; Winstock, A. R., & Barratt, M. J. (2013). The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Human Psychopharmacology: Clinical and Experimental , T. 28 , 4 , 390-393.; Freeman, M. J. (2013). et al. Ischemic stroke after use of the synthetic marijuana "spice". Neurology , T. 81 , 24 , 2090-2093.; Mir, A. (2011). et al. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics , T. 128 , 6 .; Murphy, T. D. (2013). et al. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR. Morbidity and mortality weekly report , T. 62 , 6 , 93.; Saito, T. (2013). et al. A fatal case of MAM-2201 poisoning. Forensic Toxicology , T. 31 , 2 , 333-337.; Shanks, K. G., Dahn, T., & Terrell, A. R. (2012). Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. Journal of Analytical Toxicology , T. 36 , 3 , 145-152.; Schaefer, N. (2013). et al. A fatal case involving several synthetic cannabinoids. Toxichem Krimtech , T. 80 , 248-251.; Savasman, C. M. (2014). et al. Two fatalities due to the use of synthetic cannabinoids alone. 66th Annual Meeting of the American Academy of Forensic Sciences, Seattle. Denver: Publication Printers Inc , T. 316 .; Patton, A. L. (2013). et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. Journal of forensic sciences , T. 58 , 6 , 1676-1680.; Behonick, G. (2014). et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. Journal of analytical toxicology , T. 38 , 8 , 559-562.; Corkery, J. (2013). et al. Drug-related deaths in the UK: January-December 2012. Annual report .; Elliott, S., & Evans, J. (2014). A 3-year review of new psychoactive substances in casework. Forensic science international , T. 243 , 55-60.; Kronstrand, R. (2013). et al. Toxicological findings of synthetic cannabinoids in recreational users. Journal of analytical toxicology , T. 37 , 8 , 534-541.; Rosenbaum, C. D. (2011). et al. K2 & Spice abusers: a case series of clinical and laboratory findings. CLINICAL TOXICOLOGY , 52 VANDERBILT AVE, NEW YORK, , 49 , 528-528. NY7 USA: INFORMA HEALTHCARE.; Wikstrom, M. (2012). et al. An accidental fatal intoxication with methoxetamine. Journal of analytical toxicology , T. 37 , 1 , 43-46.; Gunderson, E. W. (2012). et al. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. The American journal on addictions , T. 21 , 4 , 320-326.; Nacca, N. (2013). et al. The synthetic cannabinoid withdrawal syndrome. Journal of addiction medicine , T. 7 , 4 , 296-298.; Rominger, A. (2013). et al. Effects of acute detoxification of the herbal blend "Spice Gold" on dopamine D2. European Neuropsychopharmacology , T. 23 , 11 , 1606-1610.; Zimmermann, U. S. (2009). et al. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Deutsches Arzteblatt International , T. 106 , 27 , 464.; Celofiga, A., Koprivsek, J., & Klavz, J. (2014). Use of synthetic cannabinoids in patients with psychotic disorders: case series. Journal of dual diagnosis , T. 10 , 3 , 168-173.; Oluwabusi, O. O. (2012). et al. Synthetic cannabinoid-induced psychosis: two adolescent cases. Journal of child and adolescent psychopharmacology , T. 22 , 5 , 393-395.; Papaseit, E. (2015). et al. Human pharmacology of mephedrone: A dose-finding pilot study. Abstracts , T. 146 , 34 .; Schifano, F., Corkery, J., & Ghodse, A. H. (2012). Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. Journal of clinical psychopharmacology , T. 32 , 5 , 710-714.; Corkery, J. M., Schifano, F., & Ghodse, A. H. (2012). Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. Pharmacology. - . Intech Open.; Corkery, J. M. (2011). et al. "Bundle of fun or "bunch of problems"? Case series of khat-related deaths in the UK. Drugs , T. 18 , 6 , 408-425.; Loi, B. (2015). et al. Deaths of individuals aged 16-24 years in the UK after using mephedrone. Human Psychopharmacology: Clinical and Experimental , T. 30 , 4 , 225-232.; Warrick, B. J. (2012). et al. Lethal serotonin syndrome after methylone and butylone ingestion. Journal of Medical Toxicology , T. 8 , 1 , 65-68.; Schifano, F. (2011). et al. Mephedrone (4-methylmethcathinone; "meow meow"): chemical, pharmacological and clinical issues. Psychopharmacology , T. 214 , 3 , 593-602.; Bosak, A., & Levine, M. (2013). LoVecchio F., Recurrent seizures and serotonin syndrome following "2C-I" ingestion. Journal of medical toxicology , T. 9 , 2 , 196-198.; Topeff, J. M. (2011). et al. A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clinical Toxicology , 52 VANDERBILT AVE, NEW YORK, , 526-526. NY7 USA: INFORMA HEALTHCARE.; Schifano, F. (2010). et al. Comparison between amphetamine. Neuropsychobiology , T. 61 , 3 , 122-30.; Winstock, A., & Schifano, F. (2009). Disorders relating to the use of ecstasy, other "party drugs" and khat. New Oxford textbook of psychiatry , S. 3.5 .; Corazza, O. (2011). et al. Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Current clinical pharmacology , T. 6 , 2 , 125-129.; Bersani, F. S. (2014). et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International , T. .; Lindeman, E. (2014). et al. MT-45-en livsfarlig och potentiellt ototoxisk internetdrog. Lakartidningen , T. 111 .; Shulgin, A. (1997). TIHKAL. Berkeley: Transform Press.; Sanders, B. (2008). et al. "Research chemicals": tryptamine and phenethylamine use among high-risk youth. Substance use and misuse , T. 43 , 3 , 389-402.; Arunotayanun, W. (2013). et al. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging "novel psychoactive drugs'. Bioorganic & medicinal chemistry letters , T. 23 , 11 , 3411-3415.; Collins, M. (2011). Some new psychoactive substances: Precursor chemicals and synthesis-driven end-products. Drug testing and analysis , T. 3 , 7 , 404-416.; Lessin, A. W., Long, R. F., & Parkes, M. W. (1965). Central stimulant actions of a-alkyl substituted tryptamines in mice. British journal of pharmacology and chemotherapy , T. 24 , 1 , 49-67.; Dargan, P., & Wood, D. (2013). (ed.). Novel psychoactive substances. Academic Press.; Cozzi, N. V. (2009). et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. Journal of neural transmission , T. 116 , 12 , 1591.; Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2008). The behavioral pharmacology of hallucinogens. Biochemical pharmacology , T. 75 , 1 , 17-33.; Nichols, D. E. (2004). Hallucinogens. Pharmacology & therapeutics , T. 101 , 2 , 131-181.; Fontanilla, D. (2009). et al. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science , T. 323 , 5916 , 934-937.; Sogawa, C. (2007). et al. 5-Methoxy-N, N-diisopropyltryptamine ("Foxy"), a selective and high affinity inhibitor of serotonin transporter. Toxicology letters , T. 170 , 1 , 75-82.; Ujvary, I. (2014). Psychoactive natural products: overview of recent developments. Annali dell'Istituto superiore di sanita , T. 50 , 12-27.; Lyttle, T., Goldstein, D., & Gartz, J. (1996). Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic. Journal of Psychoactive Drugs , T. 28 , 3 , 267-290.; Wilcox, J. (2012). Psychoactive properties of alpha-methyltryptamine: analysis from self-reports of users. Journal of psychoactive drugs , T. 44 , 3 , 274-276.; Morris, H., & Wallach, J. (2014). From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug testing and analysis , T. 6 , 7 , 614-632.; Kersten, B. P. (2015). McLaughlin M. E. Toxicology and management of novel psychoactive drugs. Journal of pharmacy practice , T. 28 , 1 , 50-65.; Schifano, F. (2015). et al. Novel psychoactive substances of interest for psychiatry. World Psychiatry , T. 14 , 1 , 15-26.; Antsyborov, A. V., & Asadullin, A. R. (2017). Psikhoaktivnye effekty i toksicheskie reaktsii, sviazannye s upotrebleniem mefedrona i metilona (obzor literatury). Interaktivnaia nauka , . 19 .; Antsyborov, A. V., & Mrykhin, V. V. (2017). Sinteticheskie katinony "Soli dlia vann": mekhanizm deistviia, toksikologicheskie aspekty, klinika, formirovanie zavisimosti. Interaktivnaia nauka , . 15 .; Mrykhin, V. V., & Antsyborov, A. V. (2017). Psikhiatricheskie aspekty upotrebleniia dizainerskikh narkotikov i novykh psikhoaktivnykh veshchestv. Interaktivnaia nauka , . 12 .; Antsyborov, A. V., & Mrykhin, V. V. (2017). Sinteticheskie kannabinoidy: rasprostranionnost', mekhanizmy formirovaniia zavisimosti, psikhicheskie narusheniia, sviazannye s upotrebleniem. Sovremennoe sostoianie problemy. Interaktivnaia nauka , . 14 .
-
2Academic Journal
Συγγραφείς: ПИЧУГИНА Ю.А., БЕРЕЗОВСКАЯ М.А., КОРОБИЦИНА Т.В.
Περιγραφή αρχείου: text/html
-
3Academic Journal
Συγγραφείς: БАНТЫШ И.Б., МАРЧЕНКО М.В., НИКОЛАЕВА Э.Г., РЕБРОВА С.И., КРУПИНА Н.А.
Περιγραφή αρχείου: text/html
-
4Academic Journal
Θεματικοί όροι: ИНТОКСИКАЦИОННЫЙ ПСИХОЗ, ДИЗАЙНЕРСКИЕ НАРКОТИКИ, КУРИТЕЛЬНЫЕ СМЕСИ, ПСИХОАКТИВНЫЕ ВЕЩЕСТВА, СИНТЕТИЧЕСКИЕ КАННАБИМИМЕТИКИ
Περιγραφή αρχείου: text/html
-
5Academic Journal
Πηγή: Сибирское медицинское обозрение.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, ПСИХОАКТИВНЫЕ ВЕЩЕСТВА,СИНТЕТИЧЕСКИЕ ПСИХОСТИМУЛЯТОРЫ,СИНТЕТИЧЕСКИЕ КАННАБИМИМЕТИКИ,ШИЗОФРЕНОФОРМНЫЕ ПСИХОЗЫ,PSYCHOACTIVE SUBSTANCES,SYNTHETIC STIMULANTS,SYNTHETIC CANNABIMIMETICS,SCHIZOPHRENIFORM PSYCHOSIS, 3. Good health
Περιγραφή αρχείου: text/html
-
6Academic Journal
Πηγή: Судебная медицина.
Θεματικοί όροι: СИНТЕТИЧЕСКИЕ КАННАБИМИМЕТИКИ,ГАЗОВАЯ ХРОМАТОГРАФИЯ С МАСС-СЕЛЕКТИВНЫМ ДЕТЕКТОРОМ,ЖИДКОСТЬ-ЖИДКОСТНАЯ ЭКСТРАКЦИЯ,SYNTHETIC CANNABIMIMETICS,GC/MS,LIQUID-LIQUID EXTRACTION, 3. Good health
Περιγραφή αρχείου: text/html
-
7Academic Journal
Πηγή: Медицина и образование в Сибири.
Θεματικοί όροι: ИНТОКСИКАЦИОННЫЙ ПСИХОЗ, ДИЗАЙНЕРСКИЕ НАРКОТИКИ, КУРИТЕЛЬНЫЕ СМЕСИ, ПСИХОАКТИВНЫЕ ВЕЩЕСТВА, СИНТЕТИЧЕСКИЕ КАННАБИМИМЕТИКИ, 3. Good health
Περιγραφή αρχείου: text/html
-
8Electronic Resource
Additional Titles: New psychoactive substances: psychiatrist's view
Συγγραφείς: Анцыборов Андрей Викторович, ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России, Antsyborov Andrey Viktorovich, FSFEI of HE “Rostov State Medical University” of Russian Ministry of Health, Дубатова Ирина Владимировна, Dubatova Irina Vladimirovna
Πηγή: Interactive science; № 6(40); 57-67; Интерактивная наука; № 6(40); 57-67; ISSN: 2414-9411; 2414-9411; ISSN(electronic Version): 2500-2686; 2500-2686
Όροι ευρετηρίου: лабораторная диагностика, drug addiction, наркотическая зависимость, синтетические катиноны, designer drugs, psychosis, synthetic cathinone, new psychoactive substances, laboratory diagnostics, phenethylamines, synthetic cannabimimetic, phencyclidine, новые психоактивные вещества, фенэтиламины, фенциклидины, synthetic tryptamines, «дизайнерские» наркотики, синтетические каннабимиметики, синтетические триптамины, психотические нарушения, text, info:eu-repo/semantics/article, info:eu-repo/semantics/publishedVersion, Peer-reviewed Article
Σύνδεσμος:
https://interactive-plus.ru/files/Books/5d2efdc093510.jpeg?req=497066 https://interactive-plus.ru/e-articles/644/Action644-497066.pdf
info:eu-repo/semantics/altIdentifier/doi/10.21661/r-497066
info:eu-repo/semantics/altIdentifier/pissn/2414-9411
info:eu-repo/semantics/altIdentifier/eissn/2500-2686
Monthly international scientific journal Interactive science Issue 6(40)https://interactive-plus.ru/e-articles/644/Action644-497066.pdf
European Monitoring Centre for Drugs and Drug Addiction. EMCDDA-Europol 2013 annual report on the implementation of council decision 2005/387/JHA. – 2014.
United Nations Office on Drugs and Crime. Global Synthetic Drugs Assessment: Amphetamine-type Stimulants and New Psychoactive Substances. – United Nations Office on Drugs and Crime, 2014.
Nelson M. E., Bryant S. M., Aks S. E. Emerging drugs of abuse //Emergency Medicine Clinics. – 2014. – Т. 32. – №. 1. – С. 1–28.
Deluca P. et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project //Progress in Neuro-Psychopharmacology and Biological Psychiatry. – 2012. – Т. 39. – №. 2. – С. 221–226.
Van Hout M. C., Bingham T. «Silk Road’, the virtual drug marketplace: A single case study of user experiences //International Journal of Drug Policy. – 2013. – Т. 24. – №. 5. – С. 385–391.
Papanti D. et al. «Spiceophrenia»: a systematic overview of «Spice»-related psychopathological issues and a case report //Human Psychopharmacology: Clinical and Experimental. – 2013. – Т. 28. – №. 4. – С. 379–389.
Schifano F. Drug abuse: treatment and management //Substance Abuse Disorders. – 2009. – С. 53–74.
Schifano F. Novel psychoactive substances (NPS): clinical and pharmacological issues //Drugs and Alcohol Today. – 2015. – Т. 15. – №. 1. – С. 21–27.
Schifano F. Novel psychoactive substances also known as «legal highs’ //Annual report of the Chief Medical Officer. – 2013.
Lonati D. et al. MAM-2201 (analytically confirmed) intoxication after «synthacaine» consumption //Annals of emergency medicine. – 2014. – Т. 64. – №. 6. – С. 629–632.
Aranda E. et al. Use of novel psychoactive substances (NPS): a description of a harm reduction center in Barcelona //Res Adv Psychiatry. – 2014. – Т. 1. – №. Suppl 1. – С. 36.
Vandrey R. et al. A survey study to characterize use of Spice products (synthetic cannabinoids) //Drug and alcohol dependence. – 2012. – Т. 120. – №. 1–3. – С. 238–241.
Kikura-Hanajiri R. et al. Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012 //Forensic Toxicology. – 2013. – Т. 31. – №. 1. – С. 44–53.
Ogata J. et al. DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs //Forensic science international. – 2013. – Т. 227. – №. 1–3. – С. 33–41.
Park Y. et al. Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-methoxybenzoyl) indole //Forensic Toxicology. – 2013. – Т. 31. – №. 2. – С. 187–196.
Uchiyama N. et al. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products //Forensic science international. – 2013. – Т. 227. – №. 1–3. – С. 21–32.
Uchiyama N. et al. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl) (1-pentyl-1H-indol-3-yl) methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3, 4, 5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products //Forensic Toxicology. – 2014. – Т. 32. – №. 1. – С. 105–115.
Uchiyama N. et al. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products //Forensic Toxicology. – 2013. – Т. 31. – №. 2. – С. 223–240.
Dresen S. et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds //Journal of Mass Spectrometry. – 2010. – Т. 45. – №. 10. – С. 1186–1194.
Wurita A. et al. A large amount of new designer drug diphenidine coexisting with a synthetic cannabinoid 5-fluoro-AB-PINACA found in a dubious herbal product //Forensic Toxicology. – 2014. – Т. 32. – №. 2. – С. 331–337.
Choi H. et al. Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS //Analytical and bioanalytical chemistry. – 2013. – Т. 405. – №. 12. – С. 3937–3944.
Fattore L., Fratta W. Beyond THC: the new generation of cannabinoid designer drugs //Frontiers in behavioral neuroscience. – 2011. – Т. 5. – С. 60.
Brents L. K., Prather P. L. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products //Drug metabolism reviews. – 2014. – Т. 46. – №. 1. – С. 72–85.
Pertwee R. G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists //Current medicinal chemistry. – 2010. – Т. 17. – №. 14. – С. 1360–1381.
Papanti D. et al. «Noids» in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics //Advances in Dual Diagnosis. – 2014. – Т. 7. – №. 3. – С. 137–148.
Fišar Z. Inhibition of monoamine oxidase activity by cannabinoids //Naunyn-Schmiedeberg's archives of pharmacology. – 2010. – Т. 381. – №. 6. – С. 563–572.
Morgan D. et al. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications //Neuropharmacology. – 2013. – Т. 72. – С. 274–281.
Halberstadt A. L. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens //Behavioural brain research. – 2015. – Т. 277. – С. 99–120.
Wells D. L., Ott C. A. The «new» marijuana //Annals of Pharmacotherapy. – 2011. – Т. 45. – №. 3. – С. 414–417.
Yip L., Dart R. C. Is there something more about synthetic cannabinoids? //Forensic Toxicology. – 2014. – Т. 32. – №. 2. – С. 340–341.
Wilkinson S. M., Banister S. D., Kassiou M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids //Australian Journal of Chemistry. – 2015. – Т. 68. – №. 1. – С. 4–8.
Hermanns-Clausen M. et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings //Addiction. – 2013. – Т. 108. – №. 3. – С. 534–544.
Spaderna M., Addy P. H., D’Souza D. C. Spicing things up: synthetic cannabinoids //Psychopharmacology. – 2013. – Т. 228. – №. 4. – С. 525–540.
Winstock A. R., Barratt M. J. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products //Human Psychopharmacology: Clinical and Experimental. – 2013. – Т. 28. – №. 4. – С. 390–393.
Freeman M. J. et al. Ischemic stroke after use of the synthetic marijuana «spice» //Neurology. – 2013. – Т. 81. – №. 24. – С. 2090–2093.
Mir A. et al. Myocardial infarction associated with use of the synthetic cannabinoid K2 //Pediatrics. – 2011. – Т. 128. – №. 6. – С. e1622-e1627.
Murphy T. D. et al. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012 //MMWR. Morbidity and mortality weekly report. – 2013. – Т. 62. – №. 6. – С. 93.
Saito T. et al. A fatal case of MAM-2201 poisoning //Forensic Toxicology. – 2013. – Т. 31. – №. 2. – С. 333–337.
Shanks K. G., Dahn T., Terrell A. R. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework //Journal of Analytical Toxicology. – 2012. – Т. 36. – №. 3. – С. 145–152.
Schaefer N. et al. A fatal case involving several synthetic cannabinoids //Toxichem Krimtech. – 2013. – Т. 80. – №. Spec Iss. – С. 248–251.
Savasman C. M. et al. Two fatalities due to the use of synthetic cannabinoids alone //66th Annual Meeting of the American Academy of Forensic Sciences, Seattle. Denver: Publication Printers Inc. – 2014. – Т. 316.
Patton A. L. et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure //Journal of forensic sciences. – 2013. – Т. 58. – №. 6. – С. 1676–1680.
Behonick G. et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22 //Journal of analytical toxicology. – 2014. – Т. 38. – №. 8. – С. 559–562.
Corkery J. et al. Drug-related deaths in the UK: January-December 2012 //Annual report. – 2013.
Elliott S., Evans J. A 3-year review of new psychoactive substances in casework //Forensic science international. – 2014. – Т. 243. – С. 55–60.
Kronstrand R. et al. Toxicological findings of synthetic cannabinoids in recreational users //Journal of analytical toxicology. – 2013. – Т. 37. – №. 8. – С. 534–541.
Rosenbaum C. D. et al. K2 & Spice abusers: a case series of clinical and laboratory findings //CLINICAL TOXICOLOGY. – 52 VANDERBILT AVE, NEW YORK, NY 10017 USA: INFORMA HEALTHCARE, 2011.-Т. 49. – №. 6. – С. 528–528.
Wikström M. et al. An accidental fatal intoxication with methoxetamine //Journal of analytical toxicology. – 2012. – Т. 37. – №. 1. – С. 43–46.
Gunderson E. W. et al. «Spice» and «K2» herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans //The American journal on addictions. – 2012. – Т. 21. – №. 4. – С. 320–326.
Nacca N. et al. The synthetic cannabinoid withdrawal syndrome //Journal of addiction medicine. – 2013. – Т. 7. – №. 4. – С. 296–298.
Rominger A. et al. Effects of acute detoxification of the herbal blend «Spice Gold» on dopamine D2/3 receptor availability: a [18F] fully pride PET study //European Neuropsychopharmacology. – 2013. – Т. 23. – №. 11. – С. 1606–1610.
Zimmermann U. S. et al. Withdrawal phenomena and dependence syndrome after the consumption of «spice gold» //Deutsches Ärzteblatt International. – 2009. – Т. 106. – №. 27. – С. 464.
Celofiga A., Koprivsek J., Klavz J. Use of synthetic cannabinoids in patients with psychotic disorders: case series //Journal of dual diagnosis. – 2014. – Т. 10. – №. 3. – С. 168–173.
Oluwabusi O. O. et al. Synthetic cannabinoid-induced psychosis: two adolescent cases //Journal of child and adolescent psychopharmacology. – 2012. – Т. 22. – №. 5. – С. 393–395.
Papaseit E. et al. Human pharmacology of mephedrone: A dose-finding pilot study //Abstracts/Drug and Alcohol Dependence. – 2015. – Т. 146. – С. e34-e117.
Schifano F., Corkery J., Ghodse A. H. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, «meow meow») in the United Kingdom //Journal of clinical psychopharmacology. – 2012. – Т. 32. – №. 5. – С. 710–714.
Corkery J. M., Schifano F., Ghodse A. H. Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues //Pharmacology. – Intech Open, 2012.
Corkery J. M. et al. «Bundle of fun or «bunch of problems»? Case series of khat-related deaths in the UK //Drugs: education, prevention and policy. – 2011. – Т. 18. – №. 6. – С. 408–425.
Loi B. et al. Deaths of individuals aged 16–24 years in the UK after using mephedrone //Human Psychopharmacology: Clinical and Experimental. – 2015. – Т. 30. – №. 4. – С. 225–232.
Warrick B. J. et al. Lethal serotonin syndrome after methylone and butylone ingestion //Journal of Medical Toxicology. – 2012. – Т. 8. – №. 1. – С. 65–68.
Schifano F. et al. Mephedrone (4-methylmethcathinone; «meow meow»): chemical, pharmacological and clinical issues //Psychopharmacology. – 2011. – Т. 214. – №. 3. – С. 593–602.
Bosak A., LoVecchio F., Levine M. Recurrent seizures and serotonin syndrome following «2C-I» ingestion //Journal of medical toxicology. – 2013. – Т. 9. – №. 2. – С. 196–198.
Topeff J. M. et al. A case series of symptomatic patients, including one fatality, following 2C-E exposure //Clinical Toxicology. – 52 VANDERBILT AVE, NEW YORK, NY 10017 USA: INFORMA HEALTHCARE, 2011. – Т. 49. – №. 6. – С. 526–526.
Schifano F. et al. Comparison between amphetamine/methylamphetamine and ecstasy (MDMA, MDEA, MDA, 4-MTA) mortality data in the UK (1997–2007) //Neuropsychobiology. – 2010. – Т. 61. – №. 3. – С. 122–30.
Winstock A., Schifano F. Disorders relating to the use of ecstasy, other «party drugs» and khat //New Oxford textbook of psychiatry. – 2009. – С. 3.5.
Corazza O. et al. Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly //Current clinical pharmacology. – 2011. – Т. 6. – №. 2. – С. 125–129.
Bersani F. S. et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug //BioMed Research International. – 2014. – Т. 2014.
Lindeman E. et al. MT-45-en livsfarlig och potentiellt ototoxisk internetdrog //Lakartidningen. – 2014. – Т. 111. – С. CZR4.
Shulgin A., Shulgin A. TIHKAL: the continuation. – Berkeley: Transform Press, 1997. – Т. 546.
Sanders B. et al. «Research chemicals»: tryptamine and phenethylamine use among high-risk youth //Substance use and misuse. – 2008. – Т. 43. – №. 3–4. – С. 389–402.
Arunotayanun W. et al. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging «novel psychoactive drugs’ //Bioorganic & medicinal chemistry letters. – 2013. – Т. 23. – №. 11. – С. 3411–3415.
Collins M. Some new psychoactive substances: Precursor chemicals and synthesis-driven end-products //Drug testing and analysis. – 2011. – Т. 3. – №. 7–8. – С. 404–416.
Lessin A. W., Long R. F., Parkes M. W. Central stimulant actions of α-alkyl substituted tryptamines in mice //British journal of pharmacology and chemotherapy. – 1965. – Т. 24. – №. 1. – С. 49–67.
Dargan P., Wood D. (ed.). Novel psychoactive substances: classification, pharmacology and toxicology. – Academic Press, 2013.
Cozzi N. V. et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter //Journal of neural transmission. – 2009. – Т. 116. – №. 12. – С. 1591.
Fantegrossi W. E., Murnane K. S., Reissig C. J. The behavioral pharmacology of hallucinogens //Biochemical pharmacology. – 2008. – Т. 75. – №. 1. – С. 17–33.
Nichols D. E. Hallucinogens //Pharmacology & therapeutics. – 2004. – Т. 101. – №. 2. – С. 131–181.
Fontanilla D. et al. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator //Science. – 2009. – Т. 323. – №. 5916. – С. 934–937.
Sogawa C. et al. 5-Methoxy-N, N-diisopropyltryptamine («Foxy»), a selective and high affinity inhibitor of serotonin transporter //Toxicology letters. – 2007. – Т. 170. – №. 1. – С. 75–82.
Ujváry I. Psychoactive natural products: overview of recent developments //Annali dell'Istituto superiore di sanita. – 2014. – Т. 50. – С. 12–27.
Lyttle T., Goldstein D., Gartz J. Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic //Journal of Psychoactive Drugs. – 1996. – Т. 28. – №. 3. – С. 267–290.
Wilcox J. Psychoactive properties of alpha-methyltryptamine: analysis from self-reports of users //Journal of psychoactive drugs. – 2012. – Т. 44. – №. 3. – С. 274–276.
Morris H., Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs //Drug testing and analysis. – 2014. – Т. 6. – №. 7–8. – С. 614–632.
Kersten B. P., McLaughlin M. E. Toxicology and management of novel psychoactive drugs //Journal of pharmacy practice. – 2015. – Т. 28. – №. 1. – С. 50–65.
Schifano F. et al. Novel psychoactive substances of interest for psychiatry //World Psychiatry. – 2015. – Т. 14. – №. 1. – С. 15–26.
Анцыборов А. В., Асадуллин А. Р. Психоактивные эффекты и токсические реакции, связанные с употреблением мефедрона и метилона (обзор литературы) //Интерактивная наука. – 2017. – №. 19.
Анцыборов А. В., Мрыхин В. В. Синтетические катиноны «Соли для ванн»: механизм действия, токсикологические аспекты, клиника, формирование зависимости //Интерактивная наука. – 2017. – №. 15.
Мрыхин В. В., Анцыборов А. В. Психиатрические аспекты употребления дизайнерских наркотиков и новых психоактивных веществ //Интерактивная наука. – 2017. – №. 12.
Анцыборов А. В., Мрыхин В. В. Синтетические каннабиноиды: распространённость, механизмы формирования зависимости, психические нарушения, связанные с употреблением. Современное состояние проблемы //Интерактивная наука. – 2017. – №. 14.
European Monitoring Centre for Drugs and Drug Addiction. EMCDDA-Europol 2013 annual report on the implementation of council decision 2005.
(2014). United Nations Office on Drugs and Crime. Global Synthetic Drugs Assessment: Amphetamine-type Stimulants and New Psychoactive Substances. Drugs and Crime.
Nelson, M. E., Bryant, S. M., & Aks, S. E. (2014). Emerging drugs of abuse. Emergency Medicine Clinics, T. 32, 1, 1-28.
Deluca, P. (2012). et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Progress in Neuro-Psychopharmacology and Biological Psychiatry, T. 39, 2, 221-226.
Hout, M. C., & Bingham, T. (2013). Van, "Silk Road', the virtual drug marketplace: A single case study of user experiences. International Journal of Drug Policy, T. 24, 5, 385-391.
Papanti, D. (2013). et al. "Spiceophrenia": a systematic overview of "Spice"-related psychopathological issues and a case report. Human Psychopharmacology: Clinical and Experimental, T. 28, 4, 379-389.
Schifano, F. (2009). Drug abuse: treatment and management. Substance Abuse Disorders, S. 53.
Schifano, F. (2015). Novel psychoactive substances (NPS): clinical and pharmacological issues. Drugs and Alcohol Today, T. 15, 1, 21-27.
Schifano, F. (2013). Novel psychoactive substances also known as "legal highs'. Annual report of the Chief Medical Officer.
Lonati, D. (2014). et al. MAM-2201 (analytically confirmed) intoxication after "synthacaine" consumption. Annals of emergency medicine, T. 64, 6, 629-632.
Aranda, E. (2014). et al. Use of novel psychoactive substances (NPS): a description of a harm reduction center in Barcelona. Res Adv Psychiatry, T. 1, 1, 36.
Vandrey, R. (2012). et al. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug and alcohol dependence, T. 120, 1, 238-241.
Kikura-Hanajiri, R. (2013). et al. Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicology, T. 31, 1, 44-53.
Ogata, J. (2013). et al. DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs. Forensic science international, T. 227, 1, 33-41.
Park, Y. (2013). et al. Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-methoxybenzoyl) indole. Forensic Toxicology, T. 31, 2, 187-196.
Uchiyama, N. (2013). et al. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic science international, T. 227, 1, 21-32.
Uchiyama, N. (2014). et al. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl) (1-pentyl-1H-indol-3-yl) methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3, 4, 5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-. Forensic Toxicology, T. 32, 1, 105-115.
Uchiyama, N. (2013). et al. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative a-PVT and an opioid receptor agonis. Forensic Toxicology, T. 31, 2, 223-240.
Dresen, S. (2010). et al. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. Journal of Mass Spectrometry, T. 45, 10, 1186-1194.
Wurita, A. (2014). et al. A large amount of new designer drug diphenidine coexisting with a synthetic cannabinoid 5-fluoro-AB-PINACA found in a dubious herbal product. Forensic Toxicology, T. 32, 2, 331-337.
Choi, H. (2013). et al. Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Analytical and bioanalytical chemistry, T. 405, 12, 3937-3944.
Fattore, L., & Fratta, W. (2011). Beyond THC: the new generation of cannabinoid designer drugs. Frontiers in behavioral neuroscience, T. 5, 60.
Brents, L. K., & Prather, P. L. (2014). The K2. Drug metabolism reviews, T. 46, 1, 72-85.
Pertwee, R. G. (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Current medicinal chemistry, T. 17, 14, 1360-1381.
Papanti, D. (2014). et al. "Noids" in a nutshell: everything you (don't) want to know about synthetic cannabimimetics. Advances in Dual Diagnosis, T. 7, 3, 137-148.
Fisar, Z. (2010). Inhibition of monoamine oxidase activity by cannabinoids. Naunyn-Schmiedeberg's archives of pharmacology, T. 381, 6, 563-572.
Morgan, D. (2013). et al. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications. Neuropharmacology, T. 72, 274-281.
Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural brain research, T. 277, 99-120.
Wells, D. L., & Ott, C. A. (2011). The "new" marijuana. Annals of Pharmacotherapy, T. 45, 3, 414-417.
Yip, L., & Dart, R. C. (2014). Is there something more about synthetic cannabinoids?. Forensic Toxicology, T. 32, 2, 340-341.
Wilkinson, S. M., Banister, S. D., & Kassiou, M. (2015). Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Australian Journal of Chemistry, T. 68, 1, 4-8.
Hermanns-Clausen, M. (2013). et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction, T. 108, 3, 534-544.
Spaderna, M., & Addy, P. H. (2013). D'Souza D. C. Spicing things up: synthetic cannabinoids. Psychopharmacology, T. 228, 4, 525-540.
Winstock, A. R., & Barratt, M. J. (2013). The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Human Psychopharmacology: Clinical and Experimental, T. 28, 4, 390-393.
Freeman, M. J. (2013). et al. Ischemic stroke after use of the synthetic marijuana "spice". Neurology, T. 81, 24, 2090-2093.
Mir, A. (2011). et al. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics, T. 128, 6.
Murphy, T. D. (2013). et al. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR. Morbidity and mortality weekly report, T. 62, 6, 93.
Saito, T. (2013). et al. A fatal case of MAM-2201 poisoning. Forensic Toxicology, T. 31, 2, 333-337.
Shanks, K. G., Dahn, T., & Terrell, A. R. (2012). Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. Journal of Analytical Toxicology, T. 36, 3, 145-152.
Schaefer, N. (2013). et al. A fatal case involving several synthetic cannabinoids. Toxichem Krimtech, T. 80, 248-251.
Savasman, C. M. (2014). et al. Two fatalities due to the use of synthetic cannabinoids alone. 66th Annual Meeting of the American Academy of Forensic Sciences, Seattle. Denver: Publication Printers Inc, T. 316.
Patton, A. L. (2013). et al. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. Journal of forensic sciences, T. 58, 6, 1676-1680.
Behonick, G. (2014). et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. Journal of analytical toxicology, T. 38, 8, 559-562.
Corkery, J. (2013). et al. Drug-related deaths in the UK: January-December 2012. Annual report.
Elliott, S., & Evans, J. (2014). A 3-year review of new psychoactive substances in casework. Forensic science international, T. 243, 55-60.
Kronstrand, R. (2013). et al. Toxicological findings of synthetic cannabinoids in recreational users. Journal of analytical toxicology, T. 37, 8, 534-541.
Rosenbaum, C. D. (2011). et al. K2 & Spice abusers: a case series of clinical and laboratory findings. CLINICAL TOXICOLOGY, 52 VANDERBILT AVE, NEW YORK,, 49, 528-528. NY7 USA: INFORMA HEALTHCARE.
Wikstrom, M. (2012). et al. An accidental fatal intoxication with methoxetamine. Journal of analytical toxicology, T. 37, 1, 43-46.
Gunderson, E. W. (2012). et al. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. The American journal on addictions, T. 21, 4, 320-326.
Nacca, N. (2013). et al. The synthetic cannabinoid withdrawal syndrome. Journal of addiction medicine, T. 7, 4, 296-298.
Rominger, A. (2013). et al. Effects of acute detoxification of the herbal blend "Spice Gold" on dopamine D2. European Neuropsychopharmacology, T. 23, 11, 1606-1610.
Zimmermann, U. S. (2009). et al. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Deutsches Arzteblatt International, T. 106, 27, 464.
Celofiga, A., Koprivsek, J., & Klavz, J. (2014). Use of synthetic cannabinoids in patients with psychotic disorders: case series. Journal of dual diagnosis, T. 10, 3, 168-173.
Oluwabusi, O. O. (2012). et al. Synthetic cannabinoid-induced psychosis: two adolescent cases. Journal of child and adolescent psychopharmacology, T. 22, 5, 393-395.
Papaseit, E. (2015). et al. Human pharmacology of mephedrone: A dose-finding pilot study. Abstracts, T. 146, 34.
Schifano, F., Corkery, J., & Ghodse, A. H. (2012). Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. Journal of clinical psychopharmacology, T. 32, 5, 710-714.
Corkery, J. M., Schifano, F., & Ghodse, A. H. (2012). Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. Pharmacology. -. Intech Open.
Corkery, J. M. (2011). et al. "Bundle of fun or "bunch of problems"? Case series of khat-related deaths in the UK. Drugs, T. 18, 6, 408-425.
Loi, B. (2015). et al. Deaths of individuals aged 16-24 years in the UK after using mephedrone. Human Psychopharmacology: Clinical and Experimental, T. 30, 4, 225-232.
Warrick, B. J. (2012). et al. Lethal serotonin syndrome after methylone and butylone ingestion. Journal of Medical Toxicology, T. 8, 1, 65-68.
Schifano, F. (2011). et al. Mephedrone (4-methylmethcathinone; "meow meow"): chemical, pharmacological and clinical issues. Psychopharmacology, T. 214, 3, 593-602.
Bosak, A., & Levine, M. (2013). LoVecchio F., Recurrent seizures and serotonin syndrome following "2C-I" ingestion. Journal of medical toxicology, T. 9, 2, 196-198.
Topeff, J. M. (2011). et al. A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clinical Toxicology, 52 VANDERBILT AVE, NEW YORK,, 526-526. NY7 USA: INFORMA HEALTHCARE.
Schifano, F. (2010). et al. Comparison between amphetamine. Neuropsychobiology, T. 61, 3, 122-30.
Winstock, A., & Schifano, F. (2009). Disorders relating to the use of ecstasy, other "party drugs" and khat. New Oxford textbook of psychiatry, S. 3.5.
Corazza, O. (2011). et al. Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Current clinical pharmacology, T. 6, 2, 125-129.
Bersani, F. S. (2014). et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, T..
Lindeman, E. (2014). et al. MT-45-en livsfarlig och potentiellt ototoxisk internetdrog. Lakartidningen, T. 111.
Shulgin, A. (1997). TIHKAL. Berkeley: Transform Press.
Sanders, B. (2008). et al. "Research chemicals": tryptamine and phenethylamine use among high-risk youth. Substance use and misuse, T. 43, 3, 389-402.
Arunotayanun, W. (2013). et al. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging "novel psychoactive drugs'. Bioorganic & medicinal chemistry letters, T. 23, 11, 3411-3415.
Collins, M. (2011). Some new psychoactive substances: Precursor chemicals and synthesis-driven end-products. Drug testing and analysis, T. 3, 7, 404-416.
Lessin, A. W., Long, R. F., & Parkes, M. W. (1965). Central stimulant actions of a-alkyl substituted tryptamines in mice. British journal of pharmacology and chemotherapy, T. 24, 1, 49-67.
Dargan, P., & Wood, D. (2013). (ed.). Novel psychoactive substances. Academic Press.
Cozzi, N. V. (2009). et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. Journal of neural transmission, T. 116, 12, 1591.
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2008). The behavioral pharmacology of hallucinogens. Biochemical pharmacology, T. 75, 1, 17-33.
Nichols, D. E. (2004). Hallucinogens. Pharmacology & therapeutics, T. 101, 2, 131-181.
Fontanilla, D. (2009). et al. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science, T. 323, 5916, 934-937.
Sogawa, C. (2007). et al. 5-Methoxy-N, N-diisopropyltryptamine ("Foxy"), a selective and high affinity inhibitor of serotonin transporter. Toxicology letters, T. 170, 1, 75-82.
Ujvary, I. (2014). Psychoactive natural products: overview of recent developments. Annali dell'Istituto superiore di sanita, T. 50, 12-27.
Lyttle, T., Goldstein, D., & Gartz, J. (1996). Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic. Journal of Psychoactive Drugs, T. 28, 3, 267-290.
Wilcox, J. (2012). Psychoactive properties of alpha-methyltryptamine: analysis from self-reports of users. Journal of psychoactive drugs, T. 44, 3, 274-276.
Morris, H., & Wallach, J. (2014). From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug testing and analysis, T. 6, 7, 614-632.
Kersten, B. P. (2015). McLaughlin M. E. Toxicology and management of novel psychoactive drugs. Journal of pharmacy practice, T. 28, 1, 50-65.
Schifano, F. (2015). et al. Novel psychoactive substances of interest for psychiatry. World Psychiatry, T. 14, 1, 15-26.
Antsyborov, A. V., & Asadullin, A. R. (2017). Psikhoaktivnye effekty i toksicheskie reaktsii, sviazannye s upotrebleniem mefedrona i metilona (obzor literatury). Interaktivnaia nauka, . 19.
Antsyborov, A. V., & Mrykhin, V. V. (2017). Sinteticheskie katinony "Soli dlia vann": mekhanizm deistviia, toksikologicheskie aspekty, klinika, formirovanie zavisimosti. Interaktivnaia nauka, . 15.
Mrykhin, V. V., & Antsyborov, A. V. (2017). Psikhiatricheskie aspekty upotrebleniia dizainerskikh narkotikov i novykh psikhoaktivnykh veshchestv. Interaktivnaia nauka, . 12.
Antsyborov, A. V., & Mrykhin, V. V. (2017). Sinteticheskie kannabinoidy: rasprostranionnost', mekhanizmy formirovaniia zavisimosti, psikhicheskie narusheniia, sviazannye s upotrebleniem. Sovremennoe sostoianie problemy. Interaktivnaia nauka, . 14.
